آکامپروسات (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "آکامپروسات" in Persian language version.

refsWebsite

Global rank Persian rank

22nih.gov

4^th place

5^th place

16doi.org

2^nd place

7worldcat.org

5^th place

12^th place

4semanticscholar.org

11^th place

52^nd place

3web.archive.org

1^st place

1fda.gov

447^th place

382^nd place

1aafp.org

1,916^th place

580^th place

1qucosa.de

low place

1drugs.com

399^th place

104^th place

1webmd.com

1,169^th place

175^th place

1wiley.com

222^nd place

185^th place

1guidetopharmacology.org

low place

1psychiatryonline.org

4,032^nd place

2,052^nd place

aafp.org

Williams, SH. (2005). "Medications for treating alcohol dependence". American Family Physician. 72 (9): 1775–1780. PMID 16300039. Archived from the original on 29 September 2007. Retrieved 22 اكتبر 2022. {{cite journal}}: Check date values in: |access-date= (help)

doi.org

Plosker, GL (July 2015). "Acamprosate: A Review of Its Use in Alcohol Dependence". Drugs. 75 (11): 1255–68. doi:10.1007/s40265-015-0423-9. PMID 26084940. S2CID 19119078.
Nutt, DJ (2014). "Doing it by numbers: A simple approach to reducing the harms of alcohol". Journal of Psychopharmacology. 28 (1): 3–7. doi:10.1177/0269881113512038. PMID 24399337. S2CID 36860967.
Wilde, MI; Wagstaff, AJ (June 1997). "Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification". Drugs. 53 (6): 1038–53. doi:10.2165/00003495-199753060-00008. PMID 9179530.
Kranzler, Henry R.; Soyka, Michael (2018-08-28). "Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review". JAMA. 320 (8): 815–824. doi:10.1001/jama.2018.11406. ISSN 0098-7484. PMC 7391072. PMID 30167705.
Maisel, Natalya C.; Blodgett, Janet C.; Wilbourne, Paula L.; Humphreys, Keith; Finney, John W. (2013). "Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?". Addiction. 108 (2): 275–293. doi:10.1111/j.1360-0443.2012.04054.x. ISSN 1360-0443. PMC 3970823. PMID 23075288.
Donoghue, Kim; Elzerbi, Catherine; Saunders, Rob; Whittington, Craig; Pilling, Stephen; Drummond, Colin (2015-02-09). "The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis: The efficacy of acamprosate and naltrexone". Addiction. 110 (6): 920–930. doi:10.1111/add.12875. ISSN 0965-2140. PMID 25664494. Retrieved 2022-02-21.
Saivin, S; Hulot, T; Chabac, S; Potgieter, A; Durbin, P; Houin, G (Nov 1998). "Clinical Pharmacokinetics of Acamprosate". Clinical Pharmacokinetics. 35 (5): 331–345. doi:10.2165/00003088-199835050-00001. PMID 9839087. S2CID 34047050.
Kalk, Nicola J; Lingford-Hughes, Anne R (February 2014). "The clinical pharmacology of acamprosate". British Journal of Clinical Pharmacology. 77 (2): 315–323. doi:10.1111/bcp.12070. ISSN 0306-5251. PMC 4014018. PMID 23278595.
Mason, Barbara J.; Heyser, Charles J. (March 2010). "Acamprosate: A prototypic neuromodulator in the treatment of alcohol dependence". CNS & Neurological Disorders Drug Targets. 9 (1): 23–32. doi:10.2174/187152710790966641. ISSN 1871-5273. PMC 2853976. PMID 20201812.
Tsai, G; Coyle, JT (1998). "The role of glutamatergic neurotransmission in the pathophysiology of alcoholism". Annual Review of Medicine. 49: 173–84. doi:10.1146/annurev.med.49.1.173. PMID 9509257.
Tsai, GE; Ragan, P; Chang, R; Chen, S; Linnoila, VM; Coyle, JT (1998). "Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal". The American Journal of Psychiatry. 155 (6): 726–32. doi:10.1176/ajp.155.6.726 (inactive 31 July 2022). PMID 9619143. Archived from the original on 27 September 2011. Retrieved 22 اكتبر 2022. {{cite journal}}: Check date values in: |access-date= (help)CS1 maint: DOI inactive as of ژوئیه 2022 (link)
Reilly, Matthew T.; Lobo, Ingrid A.; McCracken, Lindsay M.; Borghese, Cecilia M.; Gong, Diane; Horishita, Takafumi; Adron Harris, R. (2008). "Effects of Acamprosate on Neuronal Receptors and Ion Channels Expressed inXenopusOocytes". Alcoholism: Clinical and Experimental Research. 32 (2): 188–196. doi:10.1111/j.1530-0277.2007.00569.x. ISSN 0145-6008. PMC 3034087.
Al Qatari, M; Khan, S; Harris, B; Littleton, J (2001). "Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain". Alcoholism: Clinical and Experimental Research. 25 (9): 1276–83. doi:10.1111/j.1530-0277.2001.tb02348.x. PMID 11584146.
Mayer, S; Harris, BR; Gibson, DA; Blanchard, JA; Prendergast, MA; Holley, RC; Littleton, J (2002). "Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus". Alcoholism: Clinical and Experimental Research. 26 (10): 1468–78. doi:10.1097/00000374-200210000-00003. PMID 12394279.
De Witte, P; Littleton, J; Parot, P; Koob, G (2005). "Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action". CNS Drugs. 19 (6): 517–37. doi:10.2165/00023210-200519060-00004. PMID 15963001. S2CID 11563216.
Möykkynen T, Korpi ER (July 2012). "Acute effects of ethanol on glutamate receptors". Basic & Clinical Pharmacology & Toxicology. 111 (1): 4–13. doi:10.1111/j.1742-7843.2012.00879.x. PMID 22429661.

drugs.com

"Acamprosate". drugs.com. 2005-03-25. Archived from the original on 22 December 2006. Retrieved 2007-01-08.

fda.gov

accessdata.fda.gov

"Campral label" (PDF). FDA. January 2012. Retrieved 27 November 2017. For label updates see FDA index page for NDA 021431

guidetopharmacology.org

"Acamprosate: Summary". IUPHAR/BPS Guide to Pharmacology. International Union of Basic and Clinical Pharmacology. Retrieved 26 November 2017. Acamprosate is a NMDA glutamate receptor antagonist and a positive allosteric modulator of GABAA receptors.
Marketed formulations contain acamprosate calcium

nih.gov

pubmed.ncbi.nlm.nih.gov

Plosker, GL (July 2015). "Acamprosate: A Review of Its Use in Alcohol Dependence". Drugs. 75 (11): 1255–68. doi:10.1007/s40265-015-0423-9. PMID 26084940. S2CID 19119078.
Williams, SH. (2005). "Medications for treating alcohol dependence". American Family Physician. 72 (9): 1775–1780. PMID 16300039. Archived from the original on 29 September 2007. Retrieved 22 اكتبر 2022. {{cite journal}}: Check date values in: |access-date= (help)
Mason, BJ (2001). "Treatment of alcohol-dependent outpatients with acamprosate: a clinical review". The Journal of Clinical Psychiatry. 62 Suppl 20: 42–8. PMID 11584875.
Nutt, DJ (2014). "Doing it by numbers: A simple approach to reducing the harms of alcohol". Journal of Psychopharmacology. 28 (1): 3–7. doi:10.1177/0269881113512038. PMID 24399337. S2CID 36860967.
Wilde, MI; Wagstaff, AJ (June 1997). "Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification". Drugs. 53 (6): 1038–53. doi:10.2165/00003495-199753060-00008. PMID 9179530.
Kranzler, Henry R.; Soyka, Michael (2018-08-28). "Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review". JAMA. 320 (8): 815–824. doi:10.1001/jama.2018.11406. ISSN 0098-7484. PMC 7391072. PMID 30167705.
Maisel, Natalya C.; Blodgett, Janet C.; Wilbourne, Paula L.; Humphreys, Keith; Finney, John W. (2013). "Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?". Addiction. 108 (2): 275–293. doi:10.1111/j.1360-0443.2012.04054.x. ISSN 1360-0443. PMC 3970823. PMID 23075288.
Donoghue, Kim; Elzerbi, Catherine; Saunders, Rob; Whittington, Craig; Pilling, Stephen; Drummond, Colin (2015-02-09). "The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis: The efficacy of acamprosate and naltrexone". Addiction. 110 (6): 920–930. doi:10.1111/add.12875. ISSN 0965-2140. PMID 25664494. Retrieved 2022-02-21.
Saivin, S; Hulot, T; Chabac, S; Potgieter, A; Durbin, P; Houin, G (Nov 1998). "Clinical Pharmacokinetics of Acamprosate". Clinical Pharmacokinetics. 35 (5): 331–345. doi:10.2165/00003088-199835050-00001. PMID 9839087. S2CID 34047050.
Kalk, Nicola J; Lingford-Hughes, Anne R (February 2014). "The clinical pharmacology of acamprosate". British Journal of Clinical Pharmacology. 77 (2): 315–323. doi:10.1111/bcp.12070. ISSN 0306-5251. PMC 4014018. PMID 23278595.
Mason, Barbara J.; Heyser, Charles J. (March 2010). "Acamprosate: A prototypic neuromodulator in the treatment of alcohol dependence". CNS & Neurological Disorders Drug Targets. 9 (1): 23–32. doi:10.2174/187152710790966641. ISSN 1871-5273. PMC 2853976. PMID 20201812.
Tsai, G; Coyle, JT (1998). "The role of glutamatergic neurotransmission in the pathophysiology of alcoholism". Annual Review of Medicine. 49: 173–84. doi:10.1146/annurev.med.49.1.173. PMID 9509257.
Tsai, GE; Ragan, P; Chang, R; Chen, S; Linnoila, VM; Coyle, JT (1998). "Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal". The American Journal of Psychiatry. 155 (6): 726–32. doi:10.1176/ajp.155.6.726 (inactive 31 July 2022). PMID 9619143. Archived from the original on 27 September 2011. Retrieved 22 اكتبر 2022. {{cite journal}}: Check date values in: |access-date= (help)CS1 maint: DOI inactive as of ژوئیه 2022 (link)
Al Qatari, M; Khan, S; Harris, B; Littleton, J (2001). "Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain". Alcoholism: Clinical and Experimental Research. 25 (9): 1276–83. doi:10.1111/j.1530-0277.2001.tb02348.x. PMID 11584146.
Mayer, S; Harris, BR; Gibson, DA; Blanchard, JA; Prendergast, MA; Holley, RC; Littleton, J (2002). "Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus". Alcoholism: Clinical and Experimental Research. 26 (10): 1468–78. doi:10.1097/00000374-200210000-00003. PMID 12394279.
De Witte, P; Littleton, J; Parot, P; Koob, G (2005). "Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action". CNS Drugs. 19 (6): 517–37. doi:10.2165/00023210-200519060-00004. PMID 15963001. S2CID 11563216.
Möykkynen T, Korpi ER (July 2012). "Acute effects of ethanol on glutamate receptors". Basic & Clinical Pharmacology & Toxicology. 111 (1): 4–13. doi:10.1111/j.1742-7843.2012.00879.x. PMID 22429661.

ncbi.nlm.nih.gov

Kranzler, Henry R.; Soyka, Michael (2018-08-28). "Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review". JAMA. 320 (8): 815–824. doi:10.1001/jama.2018.11406. ISSN 0098-7484. PMC 7391072. PMID 30167705.
Maisel, Natalya C.; Blodgett, Janet C.; Wilbourne, Paula L.; Humphreys, Keith; Finney, John W. (2013). "Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?". Addiction. 108 (2): 275–293. doi:10.1111/j.1360-0443.2012.04054.x. ISSN 1360-0443. PMC 3970823. PMID 23075288.
Kalk, Nicola J; Lingford-Hughes, Anne R (February 2014). "The clinical pharmacology of acamprosate". British Journal of Clinical Pharmacology. 77 (2): 315–323. doi:10.1111/bcp.12070. ISSN 0306-5251. PMC 4014018. PMID 23278595.
Mason, Barbara J.; Heyser, Charles J. (March 2010). "Acamprosate: A prototypic neuromodulator in the treatment of alcohol dependence". CNS & Neurological Disorders Drug Targets. 9 (1): 23–32. doi:10.2174/187152710790966641. ISSN 1871-5273. PMC 2853976. PMID 20201812.
Reilly, Matthew T.; Lobo, Ingrid A.; McCracken, Lindsay M.; Borghese, Cecilia M.; Gong, Diane; Horishita, Takafumi; Adron Harris, R. (2008). "Effects of Acamprosate on Neuronal Receptors and Ion Channels Expressed inXenopusOocytes". Alcoholism: Clinical and Experimental Research. 32 (2): 188–196. doi:10.1111/j.1530-0277.2007.00569.x. ISSN 0145-6008. PMC 3034087.

psychiatryonline.org

ajp.psychiatryonline.org

Tsai, GE; Ragan, P; Chang, R; Chen, S; Linnoila, VM; Coyle, JT (1998). "Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal". The American Journal of Psychiatry. 155 (6): 726–32. doi:10.1176/ajp.155.6.726 (inactive 31 July 2022). PMID 9619143. Archived from the original on 27 September 2011. Retrieved 22 اكتبر 2022. {{cite journal}}: Check date values in: |access-date= (help)CS1 maint: DOI inactive as of ژوئیه 2022 (link)

qucosa.de

tud.qucosa.de

Nutt, DJ (2014). "Doing it by numbers: A simple approach to reducing the harms of alcohol". Journal of Psychopharmacology. 28 (1): 3–7. doi:10.1177/0269881113512038. PMID 24399337. S2CID 36860967.

semanticscholar.org

api.semanticscholar.org

Plosker, GL (July 2015). "Acamprosate: A Review of Its Use in Alcohol Dependence". Drugs. 75 (11): 1255–68. doi:10.1007/s40265-015-0423-9. PMID 26084940. S2CID 19119078.
Nutt, DJ (2014). "Doing it by numbers: A simple approach to reducing the harms of alcohol". Journal of Psychopharmacology. 28 (1): 3–7. doi:10.1177/0269881113512038. PMID 24399337. S2CID 36860967.
Saivin, S; Hulot, T; Chabac, S; Potgieter, A; Durbin, P; Houin, G (Nov 1998). "Clinical Pharmacokinetics of Acamprosate". Clinical Pharmacokinetics. 35 (5): 331–345. doi:10.2165/00003088-199835050-00001. PMID 9839087. S2CID 34047050.
De Witte, P; Littleton, J; Parot, P; Koob, G (2005). "Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action". CNS Drugs. 19 (6): 517–37. doi:10.2165/00023210-200519060-00004. PMID 15963001. S2CID 11563216.

web.archive.org

Williams, SH. (2005). "Medications for treating alcohol dependence". American Family Physician. 72 (9): 1775–1780. PMID 16300039. Archived from the original on 29 September 2007. Retrieved 22 اكتبر 2022. {{cite journal}}: Check date values in: |access-date= (help)
"Acamprosate". drugs.com. 2005-03-25. Archived from the original on 22 December 2006. Retrieved 2007-01-08.
Tsai, GE; Ragan, P; Chang, R; Chen, S; Linnoila, VM; Coyle, JT (1998). "Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal". The American Journal of Psychiatry. 155 (6): 726–32. doi:10.1176/ajp.155.6.726 (inactive 31 July 2022). PMID 9619143. Archived from the original on 27 September 2011. Retrieved 22 اكتبر 2022. {{cite journal}}: Check date values in: |access-date= (help)CS1 maint: DOI inactive as of ژوئیه 2022 (link)

webmd.com

"Acamprosate Oral - Who should not take this medication?". WebMD.com. Retrieved 2007-01-08.

wiley.com

onlinelibrary.wiley.com

Donoghue, Kim; Elzerbi, Catherine; Saunders, Rob; Whittington, Craig; Pilling, Stephen; Drummond, Colin (2015-02-09). "The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis: The efficacy of acamprosate and naltrexone". Addiction. 110 (6): 920–930. doi:10.1111/add.12875. ISSN 0965-2140. PMID 25664494. Retrieved 2022-02-21.

worldcat.org

Kranzler, Henry R.; Soyka, Michael (2018-08-28). "Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review". JAMA. 320 (8): 815–824. doi:10.1001/jama.2018.11406. ISSN 0098-7484. PMC 7391072. PMID 30167705.
Maisel, Natalya C.; Blodgett, Janet C.; Wilbourne, Paula L.; Humphreys, Keith; Finney, John W. (2013). "Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?". Addiction. 108 (2): 275–293. doi:10.1111/j.1360-0443.2012.04054.x. ISSN 1360-0443. PMC 3970823. PMID 23075288.
Donoghue, Kim; Elzerbi, Catherine; Saunders, Rob; Whittington, Craig; Pilling, Stephen; Drummond, Colin (2015-02-09). "The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis: The efficacy of acamprosate and naltrexone". Addiction. 110 (6): 920–930. doi:10.1111/add.12875. ISSN 0965-2140. PMID 25664494. Retrieved 2022-02-21.
Kalk, Nicola J; Lingford-Hughes, Anne R (February 2014). "The clinical pharmacology of acamprosate". British Journal of Clinical Pharmacology. 77 (2): 315–323. doi:10.1111/bcp.12070. ISSN 0306-5251. PMC 4014018. PMID 23278595.
Mason, Barbara J.; Heyser, Charles J. (March 2010). "Acamprosate: A prototypic neuromodulator in the treatment of alcohol dependence". CNS & Neurological Disorders Drug Targets. 9 (1): 23–32. doi:10.2174/187152710790966641. ISSN 1871-5273. PMC 2853976. PMID 20201812.
Reilly, Matthew T.; Lobo, Ingrid A.; McCracken, Lindsay M.; Borghese, Cecilia M.; Gong, Diane; Horishita, Takafumi; Adron Harris, R. (2008). "Effects of Acamprosate on Neuronal Receptors and Ion Channels Expressed inXenopusOocytes". Alcoholism: Clinical and Experimental Research. 32 (2): 188–196. doi:10.1111/j.1530-0277.2007.00569.x. ISSN 0145-6008. PMC 3034087.
Trevor, Anthony J. (2017). "The Alcohols". In Katzung, Bertram G. (ed.). Basic & Clinical Pharmacology (14th ed.). New York. ISBN 978-1-259-64115-2. OCLC 1015240036.